Could a measles vaccine fight pancreatic cancer?

NCT ID NCT07539155

Not yet recruiting Disease control Sponsor: University of Arkansas Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether injecting the MMR vaccine directly into pancreatic tumors is safe and can help shrink them. The study will include 20 adults with borderline resectable or unresectable pancreatic cancer who have already completed standard chemotherapy and radiation. Researchers will measure immune cell changes in the tumor and track progression-free survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: MMR (measles, mumps, rubella) vaccine
What this could lead to: If it works, this could point toward a new way to treat pancreatic cancer by using the body's own immune system to attack the tumor.
What could go wrong: This is a very early, small trial with only 20 people. It is testing safety and immune response, not yet proven to shrink tumors or extend life. There is no guarantee it will work.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BORDERLINE RESECTABLE/UNRESECTABLE PANCREATIC CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

exocrine pancreatic carcinoma malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BORDERLINE RESECTABLE/UNRESECTABLE PANCREATIC CANCER NON METASTATIC PANCREATIC CANCER

More trials for these conditions

Other studies related to the condition(s) this trial covers.